Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation
- 82 Downloads
- 4 Citations
Abstract
Background
To report the effect of intravitreal injection of bevacizumab and gas for the treatment of diabetic premacular hemorrhage with active fibrovascular proliferation.
Methods
Six eyes of six consecutive patients with acute diabetic premacular hemorrhage and active fibrovascular proliferation received intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2–0.3 mL) during the same setting. All six cases had panretinal photocoagulation prior to the procedure. After treatment, patients maintained a prone position for 3 days and were followed for an average of 8 months (range, 4–13 months).
Results
All six eyes had complete reabsorption of the hemorrhage and reduction of fibrovascular proliferation. Transient vitreous opacification from breakthrough of the blood were observed in all eyes. An average of 3.8 weeks (range, 1–6 weeks) was required for the clearing of preretinal hemorrhage. Visual acuity improved in all six eyes. No recurrent bleeding or other adverse events were encountered in all cases.
Conclusions
Intravitreal injection of bevacizumab and gas may be an effective method for treating acute diabetic premacular hemorrhage with active fibrovascular proliferation.
Keywords
Bevacizumab Diabetic premacular hemorrhage Intravitreal gasReferences
- 1.Michels RG (1981) Proliferative diabetic retinopathy: pathophysiology of extraretinal complications and principles of vitreous surgery. Retina 1:1–17PubMedGoogle Scholar
- 2.O’Hanley GP, Canny CLB (1985) Diabetic dense premacular hemorrhage. A possible indication for prompt vitrectomy. Ophthalmology 92:507–511PubMedGoogle Scholar
- 3.Raymond LA (1995) Neodymium:YAG laser treatment for hemorrhages under the internal limiting membrane and posterior hyaloid face in the macula. Ophthalmology 102:406–411PubMedGoogle Scholar
- 4.Yang CM, Chen MS (2000) Tissue plasminogen activator and gas for diabetic premacular hemorrhage. Am J Ophthalmol 129:393–394 doi: 10.1016/S0002-9394(99)00393-1 PubMedCrossRefGoogle Scholar
- 5.Chung J, Kim MH, Chung SM, Chang KY (2001) The effect of tissue plasminogen activator on premacular hemorrhage. Ophthalmic Surg Lasers 32:7–12PubMedGoogle Scholar
- 6.Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614–625 doi: 10.1345/aph.1H316 PubMedCrossRefGoogle Scholar
- 7.Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278 doi: 10.1097/00006982-200603000-00004 PubMedCrossRefGoogle Scholar
- 8.Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN (1990) Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 108:259–263PubMedCrossRefGoogle Scholar
- 9.Verheul HMW, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96:4216–4221PubMedGoogle Scholar
- 10.Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216 doi: 10.1136/bjo.2007.127142 PubMedCrossRefGoogle Scholar